Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …

Obesity-related hypogonadotropic hypogonadism is a well-characterized condition in men
(termed male obesity-related secondary hypogonadism; MOSH); however, an equivalent …

The metabolic syndrome (MetS) is a cluster of clinical disorders including an unhealthy body
habitus with a large waistline, dyslipidemia, glucose intolerance and hypertension. It is …

Over the last decade, an abundance of evidence has emerged demonstrating a close link
between metabolism and immunity. It is now clear that obesity is associated with a state of …

Background A growing body of evidence has suggested that metformin potentially reduces
the risk of cancer. Our objective was to enhance the precision of estimates of the effect of …

We report here a new mitochondrial regulation occurring only in intact cells. We have
investigated the effects of dimethylbiguanide on isolated rat hepatocytes, permeabilized …

Plasma free fatty acids (FFA) play important physiological roles in skeletal muscle, heart,
liver and pancreas. However, chronically elevated plasma FFA appear to have …

Insulin signaling controls cell growth and metabolic homeostasis. Dysregulation of this
pathway causes metabolic diseases such as diabetes. Insulin signaling pathways have …

Diabetes mellitus has now assumed epidemic proportions in many countries of the world.
With the present population of 19.4 million diabetics, and approximately 60 million by the …

Insulin-like growth factor II (IGF-II) is a peptide growth factor that is homologous to both
insulin-like growth factor I (IGF-I) and insulin and plays an important role in embryonic …